## Wilfred Winston Yeo

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2181325/publications.pdf

Version: 2024-02-01

		1	1478505	1372567
11	882		6	10
papers	citations		h-index	g-index
1.2	1.2		1.2	1250
13	13		13	1250
all docs	docs citations		times ranked	citing authors

#	Article	IF	CITATIONS
1	The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70. Clinical Infectious Diseases, 2022, 74, 1459-1467.	5.8	41
2	Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. Vaccine, 2019, 37, 2482-2493.	3.8	34
3	Investigating the management of alcoholâ€related presentations in an Australian teaching hospital. Drug and Alcohol Review, 2019, 38, 190-197.	2.1	6
4	Evaluating the Effect of a Web-Based E-Learning Tool for Health Professional Education on Clinical Vancomycin Use: Comparative Study. JMIR Medical Education, 2018, 4, e5.	2.6	14
5	Spontaneous pneumomediastinum: a rare entity but not to be missed. Internal Medicine Journal, 2017, 47, 709-710.	0.8	1
6	Results of a Safety Pooled Analysis of an Adjuvanted Herpes Zoster Subunit Vaccine in More than 14,500 Participants Aged 50 Years or Older. Open Forum Infectious Diseases, 2017, 4, S416-S416.	0.9	1
7	Design and Implementation of a Novel Web-Based E-Learning Tool for Education of Health Professionals on the Antibiotic Vancomycin. Journal of Medical Internet Research, 2017, 19, e93.	4.3	25
8	Immunisation for medical researchers: an ethical and practical imperative. Medical Journal of Australia, 2016, 204, 263-263.	1.7	0
9	Quality-of-Life Impact of an Investigational Subunit-Adjuvanted Herpes Zoster Vaccine in Adults ≥50 Years of Age. Open Forum Infectious Diseases, 2016, 3, .	0.9	2
10	Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. New England Journal of Medicine, 2016, 375, 1019-1032.	27.0	752
11	Efficacy, Immunogenicity and Safety of an Investigational Subunit Adjuvanted Herpes Zoster Vaccine in Adults Aged 60 Years and Older: Results From the ZOE-50 and ZOE-70 Efficacy Studies. Open Forum Infectious Diseases, 2016, 3, .	0.9	6